A Decade At The Top: Lupin MD On Listing Adjacencies, Creating Health Care Continuum
Promoters Don’t Intend Selling Stake
As family-led firms go through a churn in India, Lupin’s MD Nilesh Gupta speaks about adding value via adjacencies to the legacy business, building digital interfaces and a healthcare continuum for patients. In an interview with Scrip, he also emphasized Lupin promoters are neither interested in selling their own stake nor in acquiring that of Cipla’s promoters.
You may also be interested in...
In an interview with Scrip, Lupin’s MD Nilesh Gupta spoke about seeking alliances to address the anti-obesity market in India post a demand surge for Wegovy and Mounjaro, the company’s thrust into pharma-adjacent businesses, the limited impact so far of the Israel-Palestine conflict on Indian pharma and more.
Self-labelled ‘disruptor’ Mark Cuban has brought on board yet another high-demand prescription drug, following a recent deal for biosimilar Humira.
CEO of Enzene Biosciences weighs in on the impact of Medicare negotiations in the US on the biosimilars market even as a US filing is planned for a Prolia biosimilar. In the interview, he says Enzene “is not afraid or concerned” over ongoing litigation with Merck KGaA over an Erbitux biosimilar in India, adding that new modalities like ADCs are being “seriously” considered.